Need a specific person's email?
Browse Mebias Discovery, Inc's employee directory (about 4 employees) and reveal verified emails free.
Mebias Discovery, Inc's most common email format is First.Last@mebiasdiscovery.com (ex. John.Doe@mebiasdiscovery.com), used for 100% of mebiasdiscovery.com addresses. Mebias Discovery, Inc uses 1 email pattern.
| Format | Example | Share of mebiasdiscovery.com |
|---|---|---|
| First.Last@mebiasdiscovery.comMost common | John.Doe@mebiasdiscovery.com |
Browse Mebias Discovery, Inc's employee directory (about 4 employees) and reveal verified emails free.
Biotechnology ResearchPennsylvania, United States2-10 Employees
Mebias Discovery, Inc. is a Philadelphia-based biotechnology company focused on discovering drugs that target G-protein coupled receptors. The firm aims to identify next-generation GPCR therapeutics with fewer on-target side effects by examining how receptors move and signal. Its platform relies on validated assays that link ligand-induced receptor conformations to pharmacologic outcomes, and the team is described as small and science-driven. Its initial focus areas include CNS-related conditions, pain, opioid use disorder, as well as metabolic and inflammatory disorders. A lead mu-opioid receptor program, MEB-1170, is presented as a differentiated biased agonist with a profile that reportedly avoids key liabilities such as respiratory depression, tolerance, and abuse potential. Public notes indicate MEB-1170 entered Phase I clinical development in late 2022, and the company publicly seeks co-development or licensing arrangements and collaborations to advance additional targets.
Most common format
First.Last@mebiasdiscovery.com
Example: John.Doe@mebiasdiscovery.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.